A cross-sectional study of chemotherapy-related AKI
X Kang, X Zheng, D Xu, T Su, Y Zhou, J Ji, Q Yu… - European Journal of …, 2021 - Springer
Purpose This study aims to detail the characteristics of chemotherapy-related acute kidney
injury (CR-AKI) and investigate its effect on patient outcomes. Methods This is a multicenter …
injury (CR-AKI) and investigate its effect on patient outcomes. Methods This is a multicenter …
[HTML][HTML] Поражение почек, ассоциированное с противоопухолевой терапией: фокус на нежелательные явления современных иммуноонкологических …
ЕС Камышова, ИН Бобкова… - Терапевтический …, 2021 - cyberleninka.ru
Ингибиторы иммунных контрольных точек (ИКТ), в том числе антиген цитотоксических
Т-лимфоцитов 4 (cytotoxic T-lymphocyte antigen 4-CTLA-4), рецептор …
Т-лимфоцитов 4 (cytotoxic T-lymphocyte antigen 4-CTLA-4), рецептор …
[HTML][HTML] 糖皮质激素在脓毒症治疗中免疫调节机制的生物信息学探索
顾杨， 张文达， 施旖旎， 李莉 - 岭南现代临床外科, 2019 - lingnanwaike.com
糖皮质激素在脓毒症治疗中免疫调节机制的生物信息学探索 欢迎访问《岭南现代临床外科》官方
网站,今天是 分享到: 首页 期刊介绍 期刊简介 编委会 数据库收录 作者中心 征稿简则 论文范例 …
网站,今天是 分享到: 首页 期刊介绍 期刊简介 编委会 数据库收录 作者中心 征稿简则 论文范例 …
[PDF][PDF] Nephrotoxicity of immune checkpoint inhibitors in immunotherapy of oncologic patients
K Szychowska, I Kurnatowska - Renal Disease and …, 2021 - journals.viamedica.pl
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed at negative
regulatory components on T cells, such as cytotoxic T lymphocyteassociated antigen 4 …
regulatory components on T cells, such as cytotoxic T lymphocyteassociated antigen 4 …
A Case Report of Successful Treatment of Severe Immunotherapy-related Hepatitis in a Patient with advanced Lung Squamous-cell carcinoma
H Zhou, A Hou, Q Liu, L Ai, M Zhan, J Wu, Y Wang… - 2023 - researchsquare.com
In the last decade, the use of immune checkpoint inhibitors (ICIs) targeting cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) and …
lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) and …
Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease
H Satoh, S Hattori - Contemporary Oncology/Współczesna Onkologia, 2022 - termedia.pl
1. Lameire NH, Levin A, Kellum JA, et al. Conference participants. Harmonizing acute and
chronic kidney disease definition and classification: report of a Kidney Disease: Improving …
chronic kidney disease definition and classification: report of a Kidney Disease: Improving …
[HTML][HTML] Лекарственно-индуцированный острый интерстициальный нефрит
ОД Остроумова, МВ Клепикова… - Сибирское …, 2021 - cyberleninka.ru
Среди причин развития острого интерстициального нефрита, на долю
индуцированного лекарственными средствами приходится от 50 до 78% всех случаев …
индуцированного лекарственными средствами приходится от 50 до 78% всех случаев …
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
M Davies, A Russo - Lung Cancer: New Understandings and Therapies, 2021 - Springer
The use of immune checkpoint inhibitors (ICPIs) is expanding rapidly to many cancer
subtypes. Clinical practice is dominated by the use of these agents. The spectrum of immune …
subtypes. Clinical practice is dominated by the use of these agents. The spectrum of immune …
[PDF][PDF] Nephro-oncology: clinical and biochemical aspects of kidney disease and cancer
AW Nowicki12, J Małyszko13 - frontierspartnerships.org
Onco-nephrology is a new field of medicine which combines many aspects of kidney injury
in cancer patients and cancers in patients with kidney disease. This connection takes many …
in cancer patients and cancers in patients with kidney disease. This connection takes many …
Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs
ES Kamyshova, IN Bobkova, MI Sekacheva - Terapevticheskii arkhiv, 2021 - ter-arkhiv.ru
Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen 4
(CTLA-4) and programmed death protein 1 (PD-1) or its ligand (PD-L1), are a new …
(CTLA-4) and programmed death protein 1 (PD-1) or its ligand (PD-L1), are a new …